arrow
T

Tavs Qvist

Rigshospitalet
H指数:18
被引数:2,000

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study

囊性纤维化患者接受Elexacaftor/Tezacaftor/Ivacaftor治疗后的健康相关生活质量及基于偏好的效用指数:一项国家登记研究

2026-11-070
OAAI
Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis

在囊性纤维化患儿和成人中,引入elexacaftor/tezacaftor/ivacaftor前后,体重、线性生长和体成分的变化。

2025-09-240
PREAI
Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial

在分枝杆菌脓肿亚种肺部疾病患者中寻找最佳治疗方案(FORMaT):一项多中心、随机、多臂、自适应平台试验

2025-09-213
OAAI
Change in pulmonary pathogens three years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohort

使用elexacaftor/tezacaftor/ivacaftor治疗三年后病原体在肺部的变化:一项在丹麦囊性纤维化队列中的观察性研究

2025-08-200
PREAI
A BEAT-PCD ERS CRC consensus statement for routine blood testing in primary ciliary dyskinesia in collaboration with PCD-Clinical Trial Network

与PCD合作的原发性纤毛运动障碍常规血液检测的BEAT-PCD ERS CRC共识声明-临床试验网络

2024-10-300
PRE
Education, employment, and income among people living with cystic fibrosis across three decades - A matched cohort study using Danish health registries
2024-09-010
PRE
Bacterial biofilms predominate in both acute and chronic human lung infections
THORAX
IF7.7
2022-01-1171
OAAI